Biosimilar Tracking Still Possible With Shared Medicare Codes, Woodcock Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA and CMS are working on a way to address pharmacovigilance through code modifiers, CDER director tells Senate panel.
You may also be interested in...
FDA Biosimilar Education Campaign Will Need To Be Targeted
Sen. Cassidy does not think additional appropriations are needed for a massive provider and patient education on biosimilars.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.
Biden vs Trump On Drug Pricing And Unfinished Business
While more significant reforms are less likely under a second Biden term unless Democrats control both chambers of Congress, former President Trump could look to put his stamp on drug pricing reform by resurrecting one of his former policies involving international reference pricing and Medicare Part B drugs.